Aratana Therapeutics Price Target Raised to $33.00 at Stifel Nicolaus (PETX)
Equities research analysts at Stifel Nicolaus hoisted their price target on shares of Aratana Therapeutics (NASDAQ:PETX) from $13.00 to $33.00 in a research note issued to investors on Friday, AnalystRatings.NET reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 33.50% from the stock’s previous close.
PETX has been the subject of a number of other recent research reports. Analysts at JMP Securities raised their price target on shares of Aratana Therapeutics from $16.00 to $38.00 in a research note to investors on Thursday. Analysts at Lazard Capital Markets raised their price target on shares of Aratana Therapeutics from $28.00 to $39.00 in a research note to investors on Tuesday, October 15th. They now have a “buy” rating on the stock. Four investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average price target of $36.67.
Shares of Aratana Therapeutics (NASDAQ:PETX) traded up 3.16% on Friday, hitting $25.50. The stock had a trading volume of 39,005 shares. Aratana Therapeutics has a 52-week low of $6.56 and a 52-week high of $15.12. The stock’s 50-day moving average is $9.38 and its 200-day moving average is $9.25. The company’s market cap is $558.3 million.
Aratana Therapeutics (NASDAQ:PETX) last released its earnings data on Monday, August 12th. The company reported ($4.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($10.21) by $5.59.
Aratana Therapeutics, Inc is a development-stage biopharmaceutical company. As of March 20, 2013, the Company has three licensed compounds in development for six product approvals in cats and dogs in each of the United States and Europe.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.